NZ521937A - Inhibition of cyclooxygenase-2 activity - Google Patents

Inhibition of cyclooxygenase-2 activity

Info

Publication number
NZ521937A
NZ521937A NZ521937A NZ52193701A NZ521937A NZ 521937 A NZ521937 A NZ 521937A NZ 521937 A NZ521937 A NZ 521937A NZ 52193701 A NZ52193701 A NZ 52193701A NZ 521937 A NZ521937 A NZ 521937A
Authority
NZ
New Zealand
Prior art keywords
dioxopiperidine
imide
phthalimido
cyclooxygenase
sieve
Prior art date
Application number
NZ521937A
Other languages
English (en)
Inventor
Andrew J Dannenberg
George W Muller
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of NZ521937A publication Critical patent/NZ521937A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
NZ521937A 2000-03-31 2001-03-30 Inhibition of cyclooxygenase-2 activity NZ521937A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19398100P 2000-03-31 2000-03-31
PCT/US2001/010581 WO2001074362A1 (en) 2000-03-31 2001-03-30 Inhibition of cyclooxygenase-2 activity

Publications (1)

Publication Number Publication Date
NZ521937A true NZ521937A (en) 2004-08-27

Family

ID=22715841

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ521937A NZ521937A (en) 2000-03-31 2001-03-30 Inhibition of cyclooxygenase-2 activity

Country Status (11)

Country Link
US (4) US20020022627A1 (US20070167479A1-20070719-C00034.png)
EP (1) EP1272189A4 (US20070167479A1-20070719-C00034.png)
JP (1) JP2003528918A (US20070167479A1-20070719-C00034.png)
KR (1) KR20030003708A (US20070167479A1-20070719-C00034.png)
CN (1) CN1420776A (US20070167479A1-20070719-C00034.png)
AU (1) AU2001249755A1 (US20070167479A1-20070719-C00034.png)
CA (1) CA2404152C (US20070167479A1-20070719-C00034.png)
MX (1) MXPA02009665A (US20070167479A1-20070719-C00034.png)
NO (1) NO20024627L (US20070167479A1-20070719-C00034.png)
NZ (1) NZ521937A (US20070167479A1-20070719-C00034.png)
WO (1) WO2001074362A1 (US20070167479A1-20070719-C00034.png)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
DE60130799T2 (de) * 2000-11-30 2008-07-17 Children's Medical Center Corp., Boston Synthese von 4-aminothalidomid enantiomeren
US7320991B2 (en) 2001-02-27 2008-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Analogs of thalidomide as potential angiogenesis inhibitors
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
NZ536908A (en) * 2002-05-17 2008-09-26 Celgene Corp Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
KR20050056247A (ko) * 2002-10-15 2005-06-14 셀진 코포레이션 골수형성이상증후군의 치료 및 관리를 위한 선택적인사이토킨 저해 약물의 사용 방법 및 이를 포함하는 조성물
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
US9006267B2 (en) 2002-11-14 2015-04-14 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20080027113A1 (en) * 2003-09-23 2008-01-31 Zeldis Jerome B Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
US7612096B2 (en) * 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
OA13284A (en) * 2003-11-06 2007-01-31 Corporation Celgene Methods and compositions using thalidomide for thetreatment and management of cancers and other dis eases.
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
NZ550026A (en) * 2004-03-22 2009-10-30 Celgene Corp Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US20080199422A1 (en) * 2004-04-14 2008-08-21 Celgene Corporation Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline
US20080213213A1 (en) * 2004-04-14 2008-09-04 Zeldis Jerome B Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
CA2563810A1 (en) * 2004-04-23 2005-11-10 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
CA2588597A1 (en) * 2004-11-23 2006-06-01 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
CL2007002218A1 (es) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
US7893045B2 (en) 2007-08-07 2011-02-22 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
HUE061382T2 (hu) 2014-08-22 2023-06-28 Celgene Corp Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva
CN106137986B (zh) * 2015-03-09 2019-04-16 常州制药厂有限公司 一种沙利度胺片及其制备方法
EP3313818B1 (en) 2015-06-26 2023-11-08 Celgene Corporation Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830991A (en) * 1954-05-17 1958-04-15 Gruenenthal Chemie Products of the amino-piperidine-2-6-dione series
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
WO1992014455A1 (en) * 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) * 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6114355A (en) * 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5731325A (en) * 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US5798368A (en) * 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
KR100539030B1 (ko) * 1996-08-12 2005-12-27 셀진 코포레이션 면역치료제 및 이를 이용하여 사이토카인 농도를 감소시키는 방법
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6590243B2 (en) * 1999-04-28 2003-07-08 Sharp Laboratories Of America, Inc. Ferroelastic lead germanate thin film and deposition method

Also Published As

Publication number Publication date
US20060199819A1 (en) 2006-09-07
NO20024627D0 (no) 2002-09-27
EP1272189A4 (en) 2004-01-14
NO20024627L (no) 2002-11-22
WO2001074362A1 (en) 2001-10-11
CN1420776A (zh) 2003-05-28
US20090156641A1 (en) 2009-06-18
US20040077686A1 (en) 2004-04-22
AU2001249755A1 (en) 2001-10-15
CA2404152A1 (en) 2001-10-11
KR20030003708A (ko) 2003-01-10
EP1272189A1 (en) 2003-01-08
US20020022627A1 (en) 2002-02-21
MXPA02009665A (es) 2005-09-08
CA2404152C (en) 2008-08-05
JP2003528918A (ja) 2003-09-30

Similar Documents

Publication Publication Date Title
CA2404152C (en) Inhibition of cyclooxygenase-2 activity
CN106660991B (zh) 抗增殖化合物及其使用方法
ES2340027T3 (es) Combinaciones para tratar el mieloma multiple.
JP2954357B2 (ja) ジドブジン、１５９２ｕ８９および３ｔｃまたはｆｔｃの相乗的組み合わせ
EA028462B1 (ru) Способы лечения немелкоклеточного рака легких на поздних стадиях c применением комбинированного лечения с ингибитором киназы tor
KR20240021884A (ko) 암을 치료하기 위한 parp 억제제와 조합된 atr 억제제의 용도
JP6381523B2 (ja) Ｐｉ−３キナーゼ阻害剤の投与レジメン
JP2016521747A5 (US20070167479A1-20070719-C00034.png)
WO2009059030A1 (en) Pyrazole derivatives as kinase inhibitors
FI120403B (fi) 4-(2-amino-6-(syklopropyyliamino)-9H-purin-9-yyli)-2-syklopenteeni-1-metanoli-sukkinaatti viruksia torjuvana aineena
TW202132285A (zh) 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法
CZ59199A3 (cs) Způsob pro inhibici exprese Fas
EP3865483A1 (en) Tlr7 agonist for treating colorectal cancer and pharmaceutical combination thereof
JP4836388B2 (ja) ｅＮＯＳ発現に起因する疾患の予防または治療薬
KR20080014017A (ko) (5ｚ)-5-(6-퀴녹살리닐메틸리덴)-2-[(2,6-디클로로페닐)아미노]-1,3-티아졸-4(5ｈ)-온
US20210220362A1 (en) Tlr7 agonist and pharmaceutical combination thereof for treating lung cancer
JP2636265B2 (ja) 脳循環改善剤
JPWO2002092096A1 (ja) 抗腫瘍剤
CN117730082A (zh) 取代的三环酰胺及其类似物的合成
CN114539229A (zh) 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
JP4384388B2 (ja) １，２−エタンジオール誘導体またはその塩を含有する切迫性尿失禁の治療薬
JP2000159690A (ja) Ｃｏｘ―２阻害剤を含有する悪液質の予防剤、又は治療剤

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: THE APPLICANTS (71) HAVE BEEN CORRECTED

RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 30 MAR 2021 BY COMPUTER PACKAGES INC

Effective date: 20140328

EXPY Patent expired